There are very many medications available for the treatment of diabetes, including oral hypoglycemic drugs like metformin, acarbose, reglaneride, and others. Insulin also includes different types of short-acting, intermediate-acting and long-acting. New drugs are constantly being developed for the treatment of diabetes.

The newest medication currently available for the treatment of diabetes should betroglitazone, which is produced and developed by the Japanese pharmaceutical giant Takeda Pharmaceuticals, is already available in Japan.

Troglitazone is aDPP-4 inhibitor. Upon administration of this class of drugs, the inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in vivo is inhibited, and as a result, the levels of endogenous GLP-1 and GIP are elevated, which further leads to increased insulin release from pancreatic β-cells. In addition, the drug simultaneously inhibits glucagon secretion to regulate blood glucose.

Troglitazone offers the following tremendous advantages over traditional hypoglycemic drugs:

This medicine only needs to be taken once a week

Currently many hypoglycemic drugs or insulin need to be taken multiple times a day, at least once a day, and some of them are so closely related to eating that application is cumbersome. Compared with other hypoglycemic drugs, troglitazone can be very convenient, especially for those who go out to socialize more.

The likelihood of hypoglycemia with troglitazone is very low

This is because troglitazone exerts an inhibitory effect on the inactivation of enteric insulin only when blood sugar is elevated. This means that the drug does not work when blood sugar is at normal levels or low. Therefore low blood sugar hardly ever occurs with troglitazone.

Because the drug is not currently available in the country, any sale of the drug in the country is currently illegal. There is no guarantee of the quality and authenticity of the drug. In addition, although the drug has relatively few side effects, it still needs to be applied under the guidance of a doctor.

We need to remind you in particular that the treatment of diabetes is a systematic treatment that includes not only medication, but also dietary control, proper exercise, etc., and the latter is of greater importance. Therefore, the treatment of diabetes must not just hope for one or two new drugs to lower blood sugar.

Exenatide, which is used to treat obesity abroad, is used in China to treat diabetics with comorbid obesity.

Now the latest exenatide microspheres were approved by the China Food and Drug Administration in January 2018 and should now be the latest drug for the treatment of diabetes. It provides a new option for the treatment of diabetics in China.

As the only and the first once-a-week GLP-1 drug in China, it releases exenatide continuously and slowly through the slow-release microsphere technology, which reduces the frequency of drug administration, reduces the gastrointestinal adverse reactions, and can significantly increase the stability of drug concentration and patients' adherence to the medication.

This medication is injected once a week, subcutaneously, 2mg at a time, and can be injected at any time and with or without food. Therefore it is very easy to administer the medication.

Application of this drug significantly reduces blood glucose, glycosylated hemoglobin and body weight. It is suitable for obese diabetics. There are no significant drug side effects, the only drawback is a slightly more expensive price.

Follow to learn more!